TSHA

Taysha Gene Therapies Inc.

Price

$6.43

return (12m)

126.41%

p/e

-14.32

p/bv

5.53

DIVIDEND YIELD

0.00%

TSHA price

Taysha Gene Therapies

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment TSHA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

12.91%

3 months

16.06%

1 year

126.41%

2 years

187.05%

5 years

-62.02%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals TSHA

Valuation

P/E

-14.32

Sector -4.38

Industry -4.38

P/BV

5.53

Sector 2.02

Industry 2.02

P/Revenue (PSR)

390.17

Sector -4.40

Industry -4.40

EV/EBITDA

-37.46

Sector -263.09

Industry -263.09

EV/EBIT

-37.23

Sector -702.90

Industry -702.90

P/EBITDA

-14.43

Sector -4.39

Industry -4.39

P/EBIT

-14.32

Sector -4.73

Industry -4.73

P/Total Assets

4.55

Sector 1.49

Industry 1.49

P/Net Current Assets

5.66

Sector -11.70

Industry -11.70

P/Working Capital

4.92

Sector -3.19

Industry -3.19

EPS

-0.41

Sector -2.14

Industry -2.14

BVPS

1.05

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-38.64%

Sector -65.14%

Industry -65.14%

ROA

-31.81%

Sector -65.53%

Industry -65.53%

ROIC

-1,026.29%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

17.76

Sector 2.90

Industry 2.90

Net Debt / EBITDA

8.76

Sector -6.07

Industry -6.07

Net Debt / EBIT

8.71

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.05

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.13

Sector -0.05

Industry -0.05

Equity/Assets

0.82

Sector 0.41

Industry 0.41

Liabilities/Assets

0.18

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-3.03%

Sector -

Industry -

Fundamentals TSHA

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
TSHA Taysha Gene Therapies Inc.	$6.43	119.45%	0.00%	-14.32	5.53	-38.64%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

TSHA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Taysha Gene Therapies

Taysha Gene Therapies Inc.

Average Investor10 user rating

4.0 (1 people)

United States

7 years

Founded: 2019

2020

Time since IPO - 6 years

10

Employees

Taysha Gene Therapies Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.14 billion, with shareholders equity totaling $387.27 million.

The company employs approximately 10 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Taysha Gene Therapies Inc. reported $5.49 million in revenue, generating net income of $-149.63 million.

Key financial metrics include a P/E ratio of -14.32, a price-to-book (P/B) ratio of 5.53, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TSHA.

Market cap

$2.14 billion

Net worth

$387.27 million

$387,270,000.00

Assets

$470.43 million

$470,430,000.00

Total Shares Outstanding

369.00 million

369,000,000

Average Daily Trading Volume

$3.34 million

$3,340,164.00

Sector

Health Care

Industry

Biotechnology

TSHA

TSHA revenue and profits

Financial Results TSHA

DRAG THE FRAME TO SEE MORE DATA

TSHA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Taysha Gene Therapies (TSHA) today?

A cotação de Taysha Gene Therapies (TSHA) hoje está em US$ 6.43, com uma variação de 126.41% em relação ao último ano. A cotação de Taysha Gene Therapies (TSHA) iniciou o ano negociando na casa dos US$ 5.50 e hoje está em US$ 6.43. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Taysha Gene Therapies (TSHA) e dados de ações do Ibovespa e mercados internacionais.

Quando Taysha Gene Therapies (TSHA) paga dividendos?

Taysha Gene Therapies (TSHA) não distribuiu dividendos no último ano.

Is Taysha Gene Therapies (TSHA) a good investment?

Atualmente, Taysha Gene Therapies (TSHA) está cotada a US$ 6.43, com um P/L de -14.32, representando um desvio de -836% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 126.41 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 126.41%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Taysha Gene Therapies (TSHA) stock?

Investir em ações de Taysha Gene Therapies (TSHA) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Taysha Gene Therapies (TSHA) yield today?

A rentabilidade de Taysha Gene Therapies (TSHA) foi de 12.91% no último mês, 126.41% no último ano e -62.02% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Taysha Gene Therapies (TSHA) hoje, o investimento total seria de US$ 643.00, com base na cotação atual de US$ 6.43.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 1,455.82
Em 5 anos: US$ 244.21
Em 10 anos: US$ 643.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

TSHA

Taysha Gene Therapies Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment TSHA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING TSHA WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Taysha Gene Therapies

Taysha Gene Therapies Inc.

United States

7 years

2020

10

PROFIT X PRICE TSHA

Financial Results TSHA

TSHA cash flow

Asset, Revenue and Profit Growth - TSHA

TSHA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions